Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude.

Abstract

Fifty-five detoxified opioid-dependent individuals were randomly assigned to 1 of 3 treatments delivered over 12 weeks: standard naltrexone maintenance, standard naltrexone plus low-value contingency management (CM), or standard naltrexone plus high-value CM. Results suggest that (a) assignment to either CM condition was associated with significant reductions in opioid use over time compared with standard naltrexone treatment; (b) contrasts of high- versus low-value reinforcement magnitude were not significant, suggesting no relative benefit of higher over lower value incentives in this population; (c) participants assigned to either CM group reported significant reductions in readiness to change compared with participants assigned to standard naltrexone treatment. These findings suggest that targeted behavioral therapies can play a substantial role in broadening the utility of available pharmacotherapies.

• Authors: Kathleen M Carroll, Rajita Sinha, Charla Nich, Theresa Babuscio, Bruce J Rounsaville
• Journal: Experimental and clinical psychopharmacology (Exp Clin Psychopharmacol) Vol. 10 Issue 1 Pg. 54-63 (Feb 2002) ISSN: 1064-1297 [Print] United States
• PMID: 11866252 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Narcotic Antagonists
• Naltrexone

Topics

• Adult
• Dose-Response Relationship, Drug
• Female
• Follow-Up Studies
• Humans
• Male
• Naltrexone (therapeutic use)
• Narcotic Antagonists (therapeutic use)
• Opioid-Related Disorders (diagnosis, drug therapy, psychology)
• Patient Compliance
• Risk-Taking
• Social Behavior
• Treatment Outcome